Stock Quote        
  Join        Login  
logo

Cross Country Healthcare (CCRN) Initiated At 'Neutral' By UBS Securities

 June 20, 2012 12:40 PM
 

(By Balaseshan) UBS Securities analyst A.J. Rice initiated coverage of Cross Country Healthcare Inc. (NASDAQ:CCRN) with a "Neutral" rating and $4.50 price target.

With $550 million in annual revenue, Cross Country is a leading pure play in medical staffing. The company has a strong presence in nurse and allied travel staffing, physician staffing and clinical trials staffing.

Cross Country's senior management team has been together since the company's IPO in 2001. The company is conservatively managed and financed, with less than $50 million in total debt.

Despite several meaningful acquisitions, CCRN's 2011 revenues were still 27% below their peak in 2003. Since the credit crisis, a number of factors have weighed on the space, such as sluggish patient volumes, the willingness of local nurses to work more shifts, and the decision by many healthcare professionals to postpone retirement.

While the need for hospitals to address "meaningful use criteria" has provided some short-term boost to staffing demand, a definitive turn in the business has been elusive. Rice's price target for CCRN of $4.50 assumes the shares can trade to about 15 times his 2013 EPS estimate over the next year.

While this valuation is well below the company's five-year average of 22 times, the analyst believes it is more reflective of the current industry backdrop that CCRN faces. Also, he noted that his expectations for 2013 EPS assume a healthy rebound in earnings over 2012.

The brokerage established its 2012 EPS estimate for the healthcare staffing services company of $0.16 and its 2013 estimate of $0.31.

CCRN is trading down 3.22% at $4.21 on Wednesday.


Rich
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.

You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.

Two Week FREE Trial


Signup for i on the market daily edition


Advertisement

Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

Advertisement
Connect with iStockAnalyst
Popular Articles
Recent Research and Quote
Advertisement
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.